Print Page | Sign In | Join Today
News & Press: Company News

Cavion Enrolls 1st Patient in Multi-Center Phase 2 Clinical Trial in Essential Tremor

Friday, September 22, 2017  
Share |
Cavion, Inc. has enrolled its first patient in its new T-CALM Study (Tremor Cav3 Modulation Study), a Phase 2 clinical trial using the company’s T-type calcium channel modulator CX-8998 for patients with Essential Tremor (ET).

Movement disorders like Essential Tremor are associated with abnormal activity of the brain’s neural networks. T-type calcium channels, called Cav3, control the firing and signaling between neurons. CX-8998 is an oral drug that was designed to selectively modulate these calcium channels, restoring the brain’s natural rhythms. Data from preclinical models suggest that CX-8998 reduces tremor by regulating abnormal neural activity in relevant brain regions.

“We are excited to enroll the first patient with Cavion’s first-in-class agent for movement disorders,” said Cavion CEO and President Andrew Krouse. “We believe that Cavion’s new therapy may significantly improve the quality of life of people with Essential Tremor, offering hope to them and their families,” added Spyros Papapetropoulos, Cavion's Executive Vice President of Research & Development and Chief Medical Officer.

“There is a tremendous need for new, safe, and effective treatments for essential tremor. The International Essential Tremor Foundation (IETF) is pleased to see a promising new approach studied in such a robust clinical trial for people with essential tremor,” said Foundation Executive Director Patrick McCartney.

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected